Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Instagram Outage Disrupts Thousands of U.S. Users 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SANTA CLARA, Calif., April 19, 2017 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has launched an e-commerce platform to support the commercialization of its Life Science products.
The launch follows the recent expansion of CrownBio’s Life Science division and answers the need to accommodate an increasing demand for the Company’s products.
CrownBio’s clients will now be able to purchase hundreds of products online across a portfolio consisting of: antibodies for in vivo and in vitro studies, recombinant proteins and cell lines, immune checkpoint antibodies, and tumor tissue microarrays.
This digital tool facilitates and accelerates clients’ ordering, enabling them to create online accounts to track the history of their previous orders, save and share quotations for pending approval, and conveniently process transactions.
“We have created a digital user-friendly experience. Our platform has been updated to meet client expectations and provide an improved opportunity to purchase and deliver products online at CrownBio,” commented Debby Saunders, Executive Director of Life Science Development at CrownBio.
“We remain impressed by the incredible growth and development of every division at CrownBio,” stated Laurie Heilmann, SVP of Global Strategy, Marketing and Business Development. “In the Life Science sector, I am pleased we could successfully pivot CrownBio digital engagement efforts with the development of the e-commerce platform, which will ensure a client friendly, efficient experience to purchasing our products.”
CrownBio’s online shop can be accessed from the company website at this link https://www.crownbio.com/shop.
For more information on CrownBio’s commitment to furthering the field of oncology and metabolic disease drug discovery, visit https://www.crownbio.com.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries: Jody Barbeau Crown Bioscience Inc. [email protected]
